Zymeworks (ZYME) EPS (Weighted Average and Diluted) (2021 - 2026)
Zymeworks recorded quarterly EPS (Weighted Average and Diluted) of -$0.59 in Q1 2026, down 7.27% quarter-over-quarter from -$0.55 in Q4 2025, and down 96.67% year-over-year from -$17.7 in Q1 2025.
Zymeworks' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.59 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 96.67% year-over-year to -$0.59; the TTM figure through Mar 2026 stood at -$1.37 (up 8.67% YoY), while the FY2025 annual figure was -$1.08, up 33.33% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.59 for Q1 2026 at Zymeworks, down from -$0.55 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.76 in Q4 2022 to a low of -$1.19 in Q1 2022.
- A 5-year average of -$0.18 and a median of -$0.41 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) surged 601.05% in 2022 and slumped 103.99% in 2023, its largest moves.
- Zymeworks' EPS (Weighted Average and Diluted) stood at $4.76 in 2022, then plunged by 103.99% to -$0.19 in 2023, then plunged by 68.42% to -$0.32 in 2024, then slumped by 71.87% to -$0.55 in 2025, then dropped by 7.27% to -$0.59 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.59, -$0.55, and -$0.26 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -0.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.59 |
| Dec 31, 2025 | -0.55 |
| Sep 30, 2025 | -0.26 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | -0.30 |
| Dec 31, 2024 | -0.32 |
| Sep 30, 2024 | -0.39 |
| Jun 30, 2024 | -0.49 |
| Mar 31, 2024 | -0.42 |
| Dec 31, 2023 | -0.19 |
| Sep 30, 2023 | -0.41 |
| Jun 30, 2023 | -0.76 |
| Mar 31, 2023 | -0.37 |
| Dec 31, 2022 | 4.76 |
| Sep 30, 2022 | -0.72 |
| Jun 30, 2022 | -0.97 |
| Mar 31, 2022 | -1.19 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -1.25 |